| Literature DB >> 34188420 |
Shailesh Desai1, Atul Munshi2,3, Devangi Munshi4.
Abstract
Even though cardiovascular disease (CVD) kills more women than men each year and remains a leading cause of death in women, it is a common misconception that women are less likely to develop CVD. Considerable sex difference exists between men and women with regard to prevention, investigations, and management of CVD. Coronary artery disease (CAD) is a major contributor to CVD morbidity and mortality and hence is specifically addressed in this article. With an explosive increase in the incidence of conventional risk factors for coronary artery disease in India, there has been an alarming increase in women's coronary events as much as men. A false sense of gender-based protection by estrogen leads to less aggressive and late prevention or management strategies that contribute to women's CAD. Metabolic syndrome (MetS) is an important contributor to future development of CAD and is also an indicator for earlier interventions for prevention. Due to physical inactivity and central obesity, MetS is more prevalent in women, especially postmenopausal. With estrogen loss, menopause marks a critical cardiovascular biological transition, with a significantly increased CVD risk in women aged >55 years. Certain female-specific risk factors, such as history of polycystic ovarian syndrome, pregnancy-induced hypertension, and gestational diabetes, also seem to play an essential role in the development of CVD in later life. Certain vascular and biological factors, such as smaller coronary vessel size, higher prevalence of small vessel disease, and lesser development of collateral flow, also play an important role. This review article is an attempt to provide important information on gender differences in CVD with specific emphasis on CAD. Copyright:Entities:
Keywords: Cardiovascular disease; coronary artery disease; estrogen; gender differences; menopause; prevention; risk factors; women
Year: 2021 PMID: 34188420 PMCID: PMC8189342 DOI: 10.4103/jmh.jmh_31_21
Source DB: PubMed Journal: J Midlife Health ISSN: 0976-7800
Age and sex distribution of 172 cases ofmetabolic syndrome
Sex/gender differences in the burden of cardiovascular disease
| Men | Women | |
|---|---|---|
| Remaining lifetime risk for CVD at age 40 y | 2 in 3 | 1 in 2 |
| CVD | ||
| Deaths caused by CVD and congenital heart disease (2007), n | 391 886 | 421 918 |
| Age-adjusted CVD death rate per 100 000 (2007) | 300.3 | 211.6 |
| Prevalence of CVD (2008, age ≥20 y), n (%) | 39 900 000(37.4) | 42 700 000(35.0] |
| Hospital discharges for CVD (2007) | 3016 000 | 2 874 000 |
| CHD | ||
| Deaths caused by CHD (2007), n | 216 050 | 190 301 |
| Age-adjusted CHD death rate per 100 000 (2007) | 165.4 | 95.7 |
| Prevalence of CHD (2008, age≥20 y), n (%) | 8 800 000(8.3) | 7 500 000(6.1) |
| Prevalence of angina pectoris (2008, age≥20 y), n (%) | 4 000 000(3.8) | 5 000 000(4.0) |
| Hospital discharges for CHD (2007), n | 965 000 | 607 000 |
| Stroke | ||
| Deaths resulting from stroke (2007, all ages) | 54111 | 81 841 |
| Age-adjusted stroke death rate per 100000 | 42.5 | 41.3 |
| Prevalence of stroke (2008, age 220 y), n (%) | 2 800 000(2.7) | 4 200 000(3.3) |
| Hospital discharges for stroke (2007), n | 371 000 | 458 000 |
| Heart failure | ||
| Prevalence of heart failure (2008, age≥20 y), n (%) | 3100 000(3.0) | 2 600 000(2.0) |
| Hospital discharges for heart failure (2007, all ages) | 470 000 | 520 000 |
| Economic burden | ||
| Percent in-hospital patient cost | 51.7 | 48.3 |
| Percent of $187 billion national cost | 57.2 | 42.8 |
Source: Heart disease and stroke statistics, American Heart Association[40]. CVD: Cardiovascular disease, CHD: Coronary heart disease
CVD Mortality
Cardiovascular Deaths
Cardiovascular disease prevention in women: What we have learned in the past decade
| Unknown in 2000 | Known in 2011 |
|---|---|
| Does MHT prevent incident CVD? | MHT does not prevent incident or recurrent CVD and increases risk of stroke in susceptible patients. MHT is safe in women without established CVD or are at low to moderate risk for CVD |
| Do SERMs prevent incident or recurrent CVD? | SERMs do not prevent incident or recurrent CVD in women and increase risk of fatal stroke and VTE |
| Is aspirin effective for the primary prevention of CVD in women? | Aspirin does not prevent incident MI in women <65 years; aspirin prevents recurrent CVD and incident ischemic stroke and might prevent incident MI in women <65 years of age but increases risk of hemorrhagic strokes and GI bleeding |
| Do antioxidant supplements prevent incident or recurrent CVD? | Vitamins E and C and beta carotene do not prevent incident or recurrent CVD |
| Do folic acid and B vitamin supplements prevent incident or recurrent CVD? | Folic acid and B vitamin supplements do not prevent incident or recurrent CVD |
| Does omega-3 fatty acid supplementation prevent incident or recurrent CVD? | Omega-3 might prevent CVD in women with hypercholesterolemia but the absolute benefit is low |
| Does vitamin D and calcium supplementation prevent incident or recurrent CVD? | Combined vitamin D (400 IU daily) and calcium supplementation (1000 mg/d) do not increase CVD risk, stroke, or mortality |
| Does intensive diabetic control prevent CVD? | Targeting HbA1C<6% does not prevent CVD events in patients with diabetes mellitus and increases the risk of death |
| Is LDL reduction effective for the primary prevention of CVD in women? | LDL reduction reduces recurrent events and might reduce incident events in women, but the absolute benefit for primary prevention is small[ |
CVD: Cardiovascular disease, SERMs: Selective estrogen receptor modulators, LDL: Low-density lipoprotein, MHT: Menopausal hormone therapy, VTE: Venous thromboembolism, MI: Myocardial infarction, GI: Gastrointestinal, HbA1C: Hemoglobin A1C